| Baseline characteristics |
Total (n = 1136) |
| Men/Women, n (%) |
770 (67.8)/366 (32.2) |
| Age at HAART initiation (years) |
|
| Mean (standard deviation) |
40 (10.4) |
| [18–50[, n (%) |
963 (84.8) |
| [50–82], n (%) |
173 (15.2) |
| Mode of HIV acquisition, n (%) |
|
| Heterosexual |
552 (48.6) |
| Homosexual/Bisexual |
389 (34.2) |
| Injection drug use |
84 (7.4) |
| Other/Unknown |
111 (9.8) |
| Year of first HAART, n (%) |
|
| [2000–2001] |
313 (27.6) |
| [2002–2003] |
242 (21.3) |
| [2004–2005] |
253 (22.3) |
| [2006–2008] |
328 (28.8) |
| Therapeutic education, Yes, n (%) |
226 (19.9) |
| First HAART regimen, n (%) |
|
| 2NRTI+1PI/1PIb ‡ |
406 (35.7) |
| 2NRTI+1NNRTI |
380 (33.5) |
| Other regimens |
350 (30.8) |
| Death, Yes, n (%) |
0 (0.0) |
| AIDS-defining illness at HAART initiation, n (%) |
|
| Yes |
151 (13.3) |
| Missing data |
44 (3.9) |
| Duration HIV seropositivity (years) |
|
| Mean (standard deviation) |
4.7 (5.7) |
| CD4 cell count at HAART initiation (cells/mm3) |
|
| Mean (standard deviation) |
264.9 (196.6) |
| Missing data, n (%) |
210 (18.5) |
| Viral load at HAART initiation (log10 copies/mm3) |
|
| Mean (standard deviation) |
4.6 (1.1) |
| Missing data, n (%) |
307(27.0) |
| ‡ PIb = boosted protease inhibitor |
|
